Overview

Folfox+Irinotecan+Chemort In Esophageal Cancer

Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer This research study involves the following study intervention: - Liposomal irinotecan
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Ipsen
Treatments:
Carboplatin
Paclitaxel